1. Home
  2. News
  3. Telix Pharmaceuticals Limited
  4. Telix and FDA Agree Resubmission Pathway for Pixclara NDA
More Telix Pharmaceuticals Limited news
Telix Pharmaceuticals LimitedASX: TLX

Telix and FDA Agree Resubmission Pathway for Pixclara NDA

Sep 8, 2025 at 10:53 PM EDT · Issued by Telix Pharmaceuticals Limited

Filed with ASX · Sep 8, 2025 at 10:53 PM EDT · 3 pages · English

On 6ix: 6ix.com/news/telix-and-fda-agree-resubmission-pathway-for-pixclara-nda

Watch Telix Pharmaceuticals' latest callTelix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call · Replay · Aug 20↗

Telix Pharmaceuticals Limited on 6ix

Earlier from Telix Pharmaceuticals

  • Telix Provides Regulatory Update on TLX250-CDxAug 27, 2025
  • Telix to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference and H.C. Wainwright 27th Annual Global Investment ConferenceAug 26, 2025
  • Telix H1 2025 Results AnnouncementAug 20, 2025
  • Telix H1 2025 Results PresentationAug 20, 2025
  • Telix H1 2025 Appendix 4D and Interim ReportAug 20, 2025

Later from Telix Pharmaceuticals

  • Telix Doses First Patient in Phase 3 BiPASS Trial: PSMA-PET Imaging for Prostate Cancer DiagnosisSep 10, 2025
  • CMS Grants Transitional Pass-Through Status for GozellixSep 22, 2025
  • Telix Announces Record-Breaking Presence at EANM 2025Sep 30, 2025
  • Telix Reports US$206M Revenue, FY 2025 Guidance UpgradedOct 14, 2025
  • TLX250-CDx (Zircaix®) Included in Leading International Guidelines for Renal ImagingOct 23, 2025
All Telix Pharmaceuticals news releases↗

Follow Telix Pharmaceuticals into a list and get an email when it puts out news.

Follow Telix Pharmaceuticals
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer